B
Beijing Huaguan Biotechnology
Provides high-quality integrated drug research and development services for customers
About Beijing Huaguan Biotechnology
Beijing Huaguan Biotechnology Co., Ltd., operating under the brand Chempion, is a vertically integrated biopharmaceutical enterprise established in 2018 with headquarters in Beijing's Haidian District. The company was founded by Dr. Chen Jian, a seasoned professional in the pharmaceutical industry. Dr. Chen holds a doctorate from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and completed postdoctoral studies at the University of Rouen in France. His extensive background includes participation in the establishment of PPDai's Beijing operations and substantial experience in both innovative drug research and development and industrial-scale production, which forms the technical foundation of the company. Since its inception, the company has undergone significant expansion, establishing a network of four R&D centers in Beijing, Nanjing, Suzhou, and Chongqing. A pivotal milestone was the 2023 acquisition of Inner Mongolia Jingdong Pharmaceutical, which now serves as its GMP-compliant active pharmaceutical ingredient (API) and key starting materials (KSMs) manufacturing base. This strategic growth has been supported by multiple funding rounds, including investments from notable entities such as Tsinghua University's Hotung Health Fund, Zhongguancun Science City Fund, and publicly listed companies like Sihuan Pharmaceutical and Xiamen Kingdomway Group. The firm's business model is centered on providing comprehensive, integrated services across the entire pharmaceutical value chain, from preclinical research to post-launch supply. Its core operations are built upon three distinct technology platforms: an advanced antibody-drug conjugate (ADC) platform, a complex molecule synthesis platform, and a platform combining continuous flow and enzymatic catalysis technologies. This infrastructure enables the company to serve a diverse clientele, including developers of innovative drugs, generic pharmaceutical manufacturers, and companies in the broader health and wellness sector. Revenue is generated by supplying materials such as APIs and intermediates, as well as offering technical services for drug development and registration.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Aug 2023
- Capital deployed
- $48M
- Preferred round
- SERIES A
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2022 | $14M | $55M | Hua Ze Jinling · Peakview Capital · Science City · Hetang Venture Capital Management (Beijing) | ↗ |
Growth signals
Latest recorded traffic for Beijing Huaguan Biotechnology is 1.1K monthly website visits, up 746.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Huaguan Biotechnology in its local ecosystem
The Beijing Huaguan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- HJHua Ze Jinling
- PCPeakview Capital
- SCScience City
- H(Hetang Venture Capital Management (Beijing)
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Huaguan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Huaguan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










